Previous 10 | Next 10 |
2024-01-31 12:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-16 08:47:27 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss Mirum stock tumbles 20% premarket on failed drug study For further details see: Mirum Pharmaceuticals appoints Quan as its chief medical officer
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum’s pipeline of programs addressing rare diseases. Dr. Quan was ...
2024-01-11 12:30:02 ET Raymond James analyst issues MARKET OUTPERFORM recommendation for MIRM on January 11, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. MIRM was trading at $26.4 at issue of the analyst recommendation. The overall analyst ...
- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89% year-over-year growth, preliminary and unaudited Mirum Pharmaceut...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare C...
2023-12-19 12:45:02 ET JMP Securities analyst issues UNDERPERFORM recommendation for MIRM on December 19, 2023 01:00PM ET. The previous analyst recommendation was Underperform. MIRM was trading at $31.41 at issue of the analyst recommendation. The overall analyst consens...
2023-12-19 09:10:24 ET Summary Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negati...
2023-12-19 07:30:02 ET Raymond James analyst issues STRONG BUY recommendation for MIRM on December 19, 2023 07:30AM ET. The previous analyst recommendation was Strong Buy. MIRM was trading at $29.385 at issue of the analyst recommendation. The overall analyst consensus :...
2023-12-18 11:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Mirum Pharmaceuticals Inc. Company Name:
MIRM Stock Symbol:
NYSE Market:
- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring abstracts Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced da...
2024-05-12 16:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million - FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March - Volixibat VISTAS and VANTAGE interim analyses scheduled for June of 2024 - Cash balanc...